The FDA approval of Optune Pax represents a significant commercial opportunity, but investors should monitor whether the company can improve margins and achieve profitability as it invests heavily in clinical trials (KEYNOTE D58, LUNAR-2) and commercialization. The reinstatement of CMS billing privileges removes a near-term regulatory risk.
Price Chart
Executive Summary
NovoCure reported 8% year-over-year revenue growth for Q4 and full year 2025, driven by increased active patients on therapy. The company received FDA approval for Optune Pax in locally advanced pancreatic cancer, a key milestone. Despite revenue growth, the company reported a net loss of $24.5 million in Q4 and guided for Adjusted EBITDA between -$20 million and $0 million in 2026 as it continues investing in clinical trials and commercialization.
Key Financial Metrics
Key Facts
- Full year 2025 revenue was $655.4 million, up 8% YoY; Q4 revenue was $174.4 million, also up 8% YoY
- FDA approved Optune Pax for locally advanced pancreatic cancer in February 2026
- Q4 2025 net loss was $24.5 million with loss per share of $0.22
- Gross margin declined to 76% from 79% in prior year due to HFE array rollout, pre-reimbursement NSCLC costs, and tariffs
- 2026 guidance: revenue of $675M-$705M and Adjusted EBITDA of -$20M to $0M
- CMS billing privileges were briefly revoked then reinstated retroactively; company expects no revenue impact
Financial Impact
Revenue growth of 8% YoY to $655.4 million in 2025, but continued losses with Q4 net loss of $24.5 million and gross margin compression from 79% to 76%
Segment Breakdown
| Segment | Revenue |
|---|---|
| Optune Gio | $174.4M |
| Optune Lua | $3.5M |
Risk Factors
- Continued gross margin pressure from HFE array rollout and pre-reimbursement costs
- Heavy R&D spending ($60.9M in Q4, up 19% YoY) delaying path to profitability
- Dependence on successful clinical trial outcomes and reimbursement approvals for new indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001645113-26-000018 |
| Document: nvcr-20260226.htm | 0001645113-26-000018 |
| Document: 0001645113-26-000018-index-headers.html | 0001645113-26-000018 |
| Document: 0001645113-26-000018-index.html | 0001645113-26-000018 |
| Document: 0001645113-26-000018.txt | 0001645113-26-000018 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $15.63 $16.38 | ▲ +4.80% | ▲ +5.13% | $14.94 (−4.41%) |
Sep 1, 2026 4w ago | 8-K | $17.38 $15.63 | ▼ −10.07% | ▼ −10.15% | $14.94 (−14.04%) |
Jul 23, 2026 10w ago | 8-K | $19.99 $15.23 | ▼ −23.81% | ▼ −24.29% | $14.94 (−25.26%) |
Jun 30, 2026 13w ago | 8-K | $15.15 $17.32 | ▲ +14.32% | ▲ +13.72% | $14.94 (−1.39%) |
Jun 18, 2026 15w ago | 8-K | $14.28 $15.05 | ▼ −5.39% | ▼ −7.06% | $14.94 (−4.62%) |
Jun 5, 2026 17w ago | 8-K | $16.85 $17.60 | ▲ +4.45% | ▲ +2.34% | $14.94 (−11.34%) |
Jun 3, 2026 17w ago | Insider Cluster | $17.99 $17.71 | ▼ −1.56% | ▲ +1.00% | $14.94 (−16.95%) |
Jun 3, 2026 17w ago | Insider Cluster | $17.99 $17.71 | ▼ −1.56% | ▲ +1.00% | $14.94 (−16.95%) |
Apr 20, 2026 23w ago | DEFA14A | $12.23 $12.12 | ▼ −0.90% | ▼ −1.98% | $14.94 (+22.16%) |
Feb 27, 2026 31w ago | Insider Cluster | $13.67 $13.04 | ▼ −4.61% | ▼ −2.63% | $14.94 (+9.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access